Every material Form 8-K enGene Therapeutics Inc. has filed with the SEC since July 17, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
enGene Therapeutics reported a third-quarter net loss of $32.5 million, or $0.47 per share, for the three months ended July 31, 2026, up from $29.0 million, or $0.57 per share, a year earlier. Total operating expenses rose to $34.0 million from $29.9 million, and the company ended the quarter with $266.3 million in cash, cash equivalents, and marketable securities, which it said will support its planned BLA submission for detalimogene.
Q3 net loss attributable to common shareholders: $32.5 million ($0.47 per share), versus $29.0 million ($0.57 per share) a year earlier
Total operating expenses: $34.0 million, versus $29.9 million; general and administrative expenses rose $6.6 million, partly due to workforce reduction-related costs
Cash, cash equivalents, and marketable securities: $266.3 million as of July 31, 2026
Pre-BLA meeting with the FDA and initiation of the detalimogene BLA submission are both planned for 4Q 2026
enGene Therapeutics hosted a virtual key opinion leader event on August 11, 2026, to present emerging non-muscle invasive bladder cancer market research, with the slide presentation filed as Exhibit 99.1. The filing contains no financial results, guidance, or transaction terms, so it provides market context rather than a change in the company's financial position.
Event held August 11, 2026; presentation filed as Exhibit 99.1 to the 8-K
Presentation cites over 65 urologist and uro-oncologist interviews and over 2,000 NMIBC patient claims as research inputs
Company states its lead drug candidate detalimogene has $285 million in cash and expects 12-month pivotal cohort data and a BLA filing in 2H 2026
enGene Therapeutics furnished an updated corporate presentation on July 17, 2026, as Exhibit 99.1 to a Form 8-K under Regulation FD. The deck restates the company's pivotal-cohort interim results for detalimogene, its plans for a BLA filing, and cash of $285 million, with no new financial results or guidance stated in the filing.
Pivotal Cohort 1 (N=125, BCG-unresponsive high-risk NMIBC with CIS) shows an any-time complete response rate of 54% (95% CI: 44.9%, 63.0%) in data as of April 21, 2026
Pivotal cohort 12-month data and BLA filing are expected in 2H 2026, with potential approval and platform designation in 2027
The company cites $285 million in cash expected to fund operations through BLA filing and potential approval
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every enGene Therapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →